These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729 [TBL] [Abstract][Full Text] [Related]
6. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses. Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004 [TBL] [Abstract][Full Text] [Related]
7. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Assudani D; Cho HI; DeVito N; Bradley N; Celis E Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170 [TBL] [Abstract][Full Text] [Related]
8. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Wu A; Zeng Q; Kang TH; Peng S; Roosinovich E; Pai SI; Hung CF Gene Ther; 2011 Mar; 18(3):304-12. PubMed ID: 20981112 [TBL] [Abstract][Full Text] [Related]
9. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells. Kawahara M; Takaku H Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871 [TBL] [Abstract][Full Text] [Related]
10. Novel H-2D McAuliffe J; Panetti S; Steffke E; Wicki A; Pereira-Almeida V; Noblecourt L; Hu Y; Guo SYW; Lesenfants J; Ramirez-Valdez RA; Chandrasekar V; Ahmad M; Stroobant V; Vigneron N; Van den Eynde BJ; Leung CSK J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39384196 [TBL] [Abstract][Full Text] [Related]
11. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. Wang C; Zainal NS; Chai SJ; Dickie J; Gan CP; Zulaziz N; Lye BKW; Sutavani RV; Ottensmeier CH; King EV; Abraham MT; Ismail SMB; Lau SH; Kallarakkal TG; Mun KS; Zain RB; Abdul Rahman ZA; Thomas GJ; Cheong SC; Savelyeva N; Lim KP Front Immunol; 2021; 12():763086. PubMed ID: 34733290 [TBL] [Abstract][Full Text] [Related]
12. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178 [TBL] [Abstract][Full Text] [Related]
13. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186 [TBL] [Abstract][Full Text] [Related]
15. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. Shirakawa T; Kitagawa K Hum Vaccin Immunother; 2018 Jan; 14(1):159-162. PubMed ID: 29048978 [TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868 [TBL] [Abstract][Full Text] [Related]
19. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]